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Abstract 
Background: Unnecessary biopsies and overdiagnosis of prostate cancer (PCa) remain a serious 
healthcare problem. We have previously shown that urine- and plasma-based prostate-specific 
biomarkers when combined can predict high grade prostate cancer (PCa). To further validate this test, 
we performed a prospective multicenter study recruiting patients from community-based practices.  
Patients and Methods: Urine and plasma samples from 2528 men were tested prospectively. Results 
were correlated with biopsy findings, if a biopsy was performed as deemed necessary by the practicing 
urologist. Of the 2528 patients, biopsy was performed on only 524 (21%) patients.  
Results: Of the 524 patients, Gleason≥3+4 PCa was found in 161 (31%) and Gleason ≥4+3 was found 
in 62 (12%) of the patients. 
The urine/plasma biomarkers algorithm showed sensitivity and specificity of 75% and 69% for predicting 
Gleason ≥3+4. However, upon incorporating prostate size and prior history of biopsy in the algorithm, 
we achieved a sensitivity between 97% and 86% and a specificity between 36% and 57%, dependent on 
the used cut-off point. Sensitivity for predicting PCa Gleason ≥4+3 was between 96% and 99% and 
specificity between 59% and 37%, dependent on the cut-off point. Diagnosis of Gleason ≥3+4 was 
missed in 1% to 3% of tested patients and of Gleason ≥4+3 in 0.2% to 1%.  
Conclusion: This test when integrated with prostate volume and the prior prostate biopsy enhance 
the sensitivity and specificity for predicting the presence of high grade prostate cancer with negative 
predictive value (NPV) of 90% to 97% for Gleason ≥3+4 and between 98% to 99% for Gleason ≥4+3. 
Key words: prostate cancer, high grade, prediction, biomarkers, urine, plasma, biopsy, Gleason. 
Introduction 
Over diagnosis and overtreatment of prostate 
cancer are significant concerns in the US healthcare 
system. More than one million prostate biopsies are 
performed each year in the US, with an attendant 
positive biopsy rate of ~40%1,2. Biopsies can lead not 
only to patient discomfort and additional healthcare 
costs, but also to significant complications in a 
minority of patients, including death3-5. Furthermore 
approximately 40-50% of patients with newly 
diagnosed PCa may have indolent disease and many 
of these patients may be best suited for an active 
surveillance strategy6.  
PSA testing remains the predominant testing 
modality for determining whether a patient considers 
 
Ivyspring  
International Publisher 
 Journal of Cancer 2017, Vol. 8 
 
http://www.jcancer.org 
2555 
a biopsy or not, despite a range of published 
controversial3,7,8 recommendations. Recently, new 
versions of measuring PSA or its isoforms are being 
introduced and showed significant improvement in 
predicting high grade prostate cancer, therefore 
reducing the need for biopsies9-11. The four kallikrein 
(4K) measures 4 isoforms of PSA, then combines the 
results with age, digital rectal exam (DRE) findings, 
and history of prior prostate Bx and generates a score 
(4KScore) for predicting the presence of aggressive 
(Gleaso≥7) PCa. In a prospective study in patients 
recommended for biopsy, the 4KScore showed an 
AUC of 0.8210.  
Another biomarker assay called PHI (Prostate 
Health index) uses a formula that incorporates 
pro-PSA, fPSA, and PSA for predicting PCa. The AUC 
was 0.70 in patients with PSA between 2 and 10 
ng/ml and negative DRE9.  
A recent study used a urine exosome-derived 
normalized RNA levels of PCA3 and ERG genes in 
combination with multiple clinical parameters (PSA 
level, age, race, and family history of PCA) reported 
distinguishing prostate cancer Gleason ≥7 from 
benign disease with AUA of 77% in the training set 
and 73% in the testing set12. 
We recently reported the development of a 
combined urine/plasma assay which measures the 
expression levels of 10 different genes in urine and 
plasma by incorporating an algorithm that includes 
serum PSA (sPSA) and age, allowing for the 
prediction biopsy proven PCa Gleason ≥3+4)13,14 
Here we report the performance of this 
urine/plasma test in randomly selected patients 
visiting urology practices for a spectrum of prostate 
issues.  
Materials and Methods 
Study Design and Patients 
Randomly selected patients from 8 different 
Urology practice sites were recruited for this study 
between July 2014 and December 2015. Inclusion 
criteria included any prostate problem or lower 
urinary tract symptoms (LUTS) (frequent or difficult 
urination, pain during urination, blood in urine) or 
elevated PSA. Exclusion criteria included prior 
diagnosis of PCa ≥7 (accepted 3+3), receiving any 
medication influencing PSA level, prostate DRE 
within 24 hours, ejaculation within 24 hours, receiving 
any cancer-related therapy, or prior prostatectomy. 
The primary outcome of the study was predicting 
biopsy results of Gleason ≥3+4 as determined in 
community-based practice using our test. The goal of 
the test is to reduce the rate of unnecessary biopsies. 
We assumed prevalence of Gleason ≥3+4 at 25% and 
power at 90%. Performing prostate biopsy was not a 
condition for recruitment, but consenting to provide 
biopsy results if performed was required. Urine and 
blood samples were collected from each patient 
without a required DRE or prostate massage and sent 
for analysis. Results of testing were not used to 
determine if biopsy is needed. All sites were asked at 
3 months post-testing to provide biopsy reports, if 
performed. All biopsies reviewed information 
required a minimum of 10 cores. All work was 
performed after obtaining institutional review board 
(IRB) approval (Western IRB).  
Urine and Plasma Processing 
The urine sample from each patient was 
concentrated and plasma was separated and RNA 
from plasma and urine was extracted as previously 
described13,14. Briefly, urine samples were 
concentrated by centrifugation using Amcion Ultra-15 
Centrifugal Filter Units with 3 kDa membrane 
(Millipore, Billerica, MA). Total nucleic acid was 
extracted from urine and plasma.  
Quantitative Reverse 
Transcription-Polymerase Chain Reaction 
Quantitative reverse transcription real time 
polymerase chain reaction (qRT-PCR) was performed 
as previously detailed13, 14. Quantitative qRT/PCR 
was performed to measure the levels of PDLIM5, 
HSPD1, IMPDH2, PCA3, TMPRSS2, ERG, UAP1, 
PTEN, AR, GAPDH and B2M RNA in urine and 
plasma.  
Statistical Analysis  
Sensitivity and specificity were calculated using 
standard formula. Comparisons between groups were 
performed using the Wilcoxon rank sum or 
Kruskal-Wallis tests for continuous variables and the 
Chi-Square test for categorical variables. Two-sided 
statistical tests were used in all analyses. Statistical 
significance considered at P-value <0.05, but 
correction for false detection rate (FDR) due to 
multiple testing is also used and expressed as q-value. 
Relationships among groups were investigated using 
Fisher’s exact test for categorical variables. For 
developing the new model univariate and 
multivariate logistic regression analysis was 
performed.  
Results 
Prediction high grade PCa using biomarkers 
only 
Between July 2014 and December 2015, a total of 
2528 patients were enrolled in this study. Treating 
physicians elected to perform biopsies within three 
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months on only 524 (21%) of these patients based on 
their clinical judgment and current standard practice. 
All enrolled patients were randomly selected. All 
enrolled patients were referred to urologists because 
of lower urinary tract symptoms. However, low level 
of PSA was not an exclusion criterion. Patients with 
prior biopsy and diagnosis of PCa Gleason 6 were 
accepted since the goal of this study is to predict high 
grade cancer. We excluded patients with prior 
diagnosis of PCa Gleason ≥7, receiving any 
medication influencing PSA level, prostate DRE 
within 24 hours, ejaculation within 24 hours, receiving 
any cancer-related therapy, or prior prostatectomy. 
PSA in these 524 patients was <4 ng/ml in 78 (15%) 
and >10 ng/ml in 63 (12%) of these patients (Table 1). 
The median age was 65 years (range: 40-89). The 
median prostate size was 40 g (range: 3.8-251 g). The 
majority of patients (404, 77%) were caucasian. 
African American were 15% (N=80). Nineteen percent 
(N=99) of these patients had prior biopsy and 4% 
(N=22) of all patients had prior diagnosis of PCa 
Gleason 3+3.  
 
Table 1. Patients characteristics. 
Age 65 (40-89) 
Prostate size (gm) 40 (3.8-251) 
Gleason  
3+3 109 (21%) 
3+4 99 (19%) 
≥4+3 62 (12%) 
sPSA (ng/ml)  
≤4 78 (15%) 
4 to 10 383 (73%) 
>10 63 (12%) 
Race  
Caucasian 404 (77%) 
African American 80 (15%) 
Hispanic 7 (1%) 
Asian 1 (0.2%) 
Missing 32 (6%) 
Family History  
Yes 84 (16%) 
No 299 (57%) 
Unknown 141 (27%) 
Prior Biopsy  
Yes, Negative 77 (15%) 
Yes, Positive 22 (4%) 
No 425 (81%) 
DRE  
Normal 347 (66%) 
Abnormal 44 (8%) 
Unknown 133 (25%) 
Stage  
T1a 14 (3%) 
T1b 56 (11%) 
T1c 154 (29%) 
T2a 10 (2%) 
T2b 6 (1%) 
T2c 9 (2%) 
 
Patients who underwent biopsy included 270 
(51%) patients with cancer. Biopsy data showed 109 
(21%) patients with Gleason 3+3, 99 (19%) with 
Gleason 3+4, and 62 (12%) with Gleason ≥4+3 PCa 
and the rest were negative. Cases with Gleason 3+4 
are defined by having major cancer pattern as grade 3 
and minor component as grade 3 and the opposite is 
true for Gleason 4+3. Using the urine/plasma 
biomarkers algorithm without any modification, we 
predicted the presence of cancer in 234 patients. 
However, PCa Gleason ≥3+4 was reported on biopsy 
in 40 patients that were missed by the urine/plasma 
test. Of these 40 patients, only 11 had PCa Gleason 
≥4+3. The sensitivity and specificity of the test was at 
75% and 69% (respectively) for predicting Gleason 
≥3+4 (Table 2), but they were 82% and 61% for 
predicting Gleason ≥4+3 (Table 3). If the test 
recommendations were followed, there was a risk of 
missing or delaying diagnosis of Gleason ≥3+4 in 8% 
or missing/delaying diagnosis of Gleason ≥4+3 in 2% 
of patients. The negative predictive value of the 
urine/plasma test was at 86% for patients with 
Gleason ≥3+4 (Table 2) and 96% for patients with 
Gleason ≥4+3 (Table 3). The prevalence of Gleason 
≥3+4 in this group of patients was 31%, which is 
higher than the reported by other studies10.  
To rule out a bias in the patient population who 
underwent biopsy procedure, we compared the score 
between those with biopsy and those without biopsy. 
There was no significant difference in the overall score 
between the two groups (P=0.36, Kruskal-Wallis test). 
However, overall, 25% of patients were predicted by 
the test to have Gleason ≥3+4.  
 
 
Table 2. Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for predicting Gleason ≥ 3+4.  
  
  
Estimated Value 95% Confidence Interval 
Lower Limit Upper Limit 
Sensitivity 75% 68% 81% 
Specificity 69% 64% 74% 
PPV 52% 45% 58% 
NPV 86% 82% 90% 
 
 
Table 3. Sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for predicting Gleason ≥ 4+3. 
  
  
Estimated Value 95% Confidence Interval 
Lower Limit Upper Limit 
Sensitivity 82% 70% 90% 
Specificity 61% 56% 65% 
PPV 22% 17% 28% 
NPV 96% 93% 98% 
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Incorporating clinical information with bio-
markers in predicting biopsy high grade PCa 
Since prior studies have shown that clinical 
information may significantly improve prediction of 
the presence of PCa15, we explored the potential of 
using available clinical information on improving the 
prediction of the presence of aggressive PCa. This 
included race, DRE data, history of prior biopsy, 
family history, and prostate size. Only 489 patients 
had the most complete information on these clinical 
variables. Univariate analysis showed that prostate 
size associated significantly with the presence of 
aggressive PCa (P=0.00001/q=0.0004). More 
specifically, patients with aggressive PCa tend to have 
lower prostate size. In addition, history of prior 
prostate biopsy associated directly with the presence 
of aggressive PCa (P=0.003/q=0.02). We combined 
urine/plasma biomarkers algorithm with prostate 
size in a decision tree and dichotomized patients into 
two groups: one includes high proportion of patients 
with aggressive PCa and a second group that includes 
high proportion of patients with non-aggressive PCa. 
We further refined the prediction in each group using 
logistic models based on history of prior biopsy along 
with urine/plasma biomarkers and developed two 
independent algorithms: one for prediction of biopsy 
results in the group with high proportion of patients 
with aggressive PCa and one for prediction of biopsy 
results in the second group with high proportion of 
patients with non-aggressive PCa. The scores 
obtained from the two logistic models, when 
incorporated together in analyzing patients, showed 
significantly higher sensitivity and specificity 
dependent on the cut-off used (Table 4) (Fig. 1). As 
shown in Figure 1, area under the curve (AUC) of 
sPSA was at 54.4%. Combining the clinical 
information (age, prostate size, and history of prior 
biopsy) improved the AUC to 73.6%, but our final 
algorithm that also incorporated the urine and plasma 
biomarkers significantly improved the AUC to 81.5%.  
 
Table 4. Sensitivity and specificity after integrating prostate size 
and history of prior biopsy into the biomarkers algorithm and 
analyzing the group with high proportion of non-aggressive patient 
in a separate algorithm (Logistic 1) and the group with the high 
proportion of aggressive patients in a second algorithm (Logistic 
2). The sensitivity of specificity at various cut-off points are shown.  
  Logistic 2 
Logistic 1 Sensitivity 0.10 0.15 0.20 0.25 0.30 
 0.10 0.973 0.952 0.946 0.925 0.905 
0.15 0.946 0.925 0.918 0.898 0.878 
0.20 0.912 0.891 0.884 0.864 0.844 
0.25 0.878 0.857 0.850 0.830 0.810 
0.30 0.857 0.837 0.830 0.810 0.789 
  Logistic 2 
Logistic 1 Specificity 0.10 0.15 0.20 0.25 0.30 
0.10 0.363 0.377 0.401 0.447 0.465 
0.15 0.442 0.456 0.480 0.526 0.544 
0.20 0.506 0.520 0.544 0.591 0.608 
0.25 0.544 0.558 0.582 0.629 0.646 
0.30 0.570 0.585 0.608 0.655 0.673 
 
 
 
Figure 1. Receiver operating characteristic (ROC) curve showing the area under the curve (AUC) of serum PSA (sPSA), clinical information, combined clinical 
information with sPSA, and the final algorithm that incorporate the urine and plasma biomarkers with sPSA and clinical information.  
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Table 5. Predicted and actual data for selected three cut-off points with overall sensitivity, specificity, PPV and NPV for predicting patients 
with PCa ≥3+4 and patients with PCa Gleason ≥4+3. The number of cases missed by the algorithm were 16, 2, and 3 for Gleason 3+4, 4+3, 
and ≥4+3, respectively, using low cut-off; 9, 1, and 3 for Gleason 3+4, 4+3, and ≥4+3, respectively, using standard cut-off; and 3, 0, and 1 
for Gleason 3+4, 4+3, and ≥4+3, respectively, using high cut-off.  
  Cut-off Neg 3+3 3+4 4+3 >4+3 Total Missed Sensitivity  Specificity  NPV PPV 
≥3+4 ≥4+3 ≥3+4 ≥4+3 ≥3+4 ≥4+3 ≥3+4 ≥4+3 
Actual   239 103 92 29 26                   
Predicted  Low 93 54 76 27 23 21 (4.3%) 86% 96% 57% 59% 90% 98% 46% 46% 
Standard 106 63 83 28 23 13 (2.7%) 91% 97% 51% 44% 93% 98% 44% 52% 
High 148 70 89 29 25 4 (0.8%) 97% 99% 36% 37% 97% 99% 40% 40% 
 
 
 
For clinically practical approach, we selected 
three cut-off point: standard, high and low. These 
cut-off points show sensitivity at 91%, 97%, and 86% 
and specificity at 51%, 36%, and 57%, respectively for 
predicting PCa Gleason ≥ 3+4 (Table 5). However, the 
sensitivity is significantly higher for predicting the 
presence of PCa Gleason ≥4+3 (Table 5).  
Discussion 
This prospective multicenter study showed a 
high sensitivity and specificity, negative predictive 
value for predicting Gleason ≥7 using biomarkers in 
urine and peripheral blood plasma for the prediction 
of prostate biopsy findings. The purpose of the test is 
to reduce unnecessary biopsies and to select patients 
who would benefit from the diagnosis of a significant 
PCa. The assay was offered as an option to 
community-based practicing urologists without the 
condition of performing biopsy. Treating urologists 
determined to perform biopsy based on their clinical 
judgment. The study is designed to reduce the rate of 
unnecessary biopsies in urology community practices. 
Since the purpose of performing a biopsy in a specific 
patient is to find out if this patient has Gleason grade 
≥3+4 as determined by community-based practitioner, 
we designed the study to collect samples from these 
patients and correlate test results with biopsy results 
in these patients. This will allow us to determine how 
many of these patients will avoid performing biopsy if 
this test is performed.  
 Per the design of the trial, information on biopsy 
was collected at three months of performing the test. 
This showed that 21% of the enrolled patients 
underwent prostate biopsy. This most likely reflects 
the rate of performing biopsy in general practice at 
this time. Interestingly, of these patients only 51.5% 
had prostate cancer on biopsy, but more importantly 
only 31% had PCa Gleason ≥3+4, which suggests that 
69% of the biopsied patients had no cancer or 
indolent/clinically insignificant cancer. This is 
significant issue in routine clinical practice, since 
performing biopsy is not without consequences of 
bleeding and infection.  
Toward this goal, we developed a test that 
combines biomarkers in urine and peripheral blood 
plasma. These biomarkers have been previously 
described12,13. They include: PDLIM5, HSPD1, 
IMPDH2, PCA3, TMPRSS2, ERG, UAP1, PTEN, AR, 
GAPDH and B2M in addition to the serum PSA 
(sPSA) protein and age. These biomarkers were 
previously validated by studying their levels in 
patients with confirmed PCa and by comparing their 
levels with the levels in patients with benign prostate 
hyperplasia as well as with the levels in patients after 
prostatectomy12.  
We first tested the performance of the algorithm 
as it was previously described without any 
modification. The urine/plasma original algorithm 
recommended performing biopsy to confirm or rule 
out PCa Gleason ≥3+4 in 45% of the patients. It 
accurately detected the presence or absence of 
prostate cancer in 70.8% of patients. Recommended 
unnecessary biopsy in 21.5% of patients. It accurately 
predicted the presence of PCa Gleason ≥3+4 in 23% of 
all patients. However, 7.6% of patients were 
misclassified as they do not need biopsy or lack the 
presence of PCa, but actually had PCa Gleason ≥3+4. 
The algorithm missed 2% of the patients with PCa 
Gleason ≥4+3. The original algorithm had NPV of 96% 
for Gleason ≥4+3.  
This study proved that the urine/plasma 
biomarkers are reliable and show reproducible results 
in predicting high grade PCa. However, it misses the 
diagnosis of significant number of patients. To 
improve the performance of this test, we took 
advantage of some clinical parameters and 
incorporated these parameters in the prediction 
model. While this was not pre-planned in the study, 
but clinical parameters are constant and not part of 
the laboratory testing, therefore, including them in a 
final analysis may improve the prediction without 
influencing the testing. Univariate analysis showed 
that prostate size and history of prior biopsy are 
highly predictive of the presence of aggressive PCa. 
Therefore, we incorporated these two clinical 
variables in our biomarkers model and modified the 
current algorithm. If clinical data was not available for 
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a specific patient, a median equivalent was used and 
the score was calculated. Incorporating clinical 
information in the algorithm lead to significant 
improvement in the sensitivity and NPV (Fig 1).  
 We selected three cut-off points: standard, low 
and high. As demonstrated in table 5, the high cut-off 
point provides very high sensitivity and NPV but the 
standard cut-off is also very practical with NPV at 
93% for PCa Gleason ≥3+4 and 98% for ≥4+3. With the 
standard cut-off point, 38% of patients will avoid 
performing biopsy and only 2.7% of patients with 
Gleason ≥3+4 would have a delayed diagnosis. 
Choosing which cut-off point to use for determining if 
biopsy should be performed should be based on other 
clinical findings and discussion with the patient. For 
example, a patient over the age of 70, might tolerate 
higher risk and accept low cut-off point as compared 
to a patient at younger age or to a patient with strong 
family history.  
The results of this study show that this 
urine/plasma test is reliable in reducing unnecessary 
biopsies and highly reliable in ruling out high grade 
(Gleason ≥4+3) prostate cancer. Most likely the levels 
of the analyzed biomarkers in peripheral blood 
plasma and urine reflect the expected higher levels of 
turnover of tumor cells in more aggressive or higher 
grade PCa. Tumor cells with higher turnover pour 
more of their RNA/DNA into blood and urine. 
Therefore, when properly measured, they can be used 
for predicting the aggressiveness of the cancer. This 
test is not totally relying on measuring PSA or PSA 
isoforms. Therefore, it can be combined with other 
tests such as 4KScore or PHI for managing and 
screening patients with potential prostate cancer. The 
prevalence of PCa Gleason ≥3+4 in our series was at 
31%, slightly higher than that reported in the 4k 
stud.10 If we adjust the prevalence of Gleason ≥3+4 to 
23%, the NPV of our urine/plasma test changes and 
will become even higher, but based on our data, most 
likely the prevalence of high grade PCa is higher than 
23% and our data is more representative of todays 
practice.  
 This test could be very useful in monitoring 
elderly man with elevated PSA avoiding performing a 
biopsy. Some of these men will have an insignificant 
cancer and would be more clinically useful to be 
monitored using this test in watchful waiting 
program.  
Since our model incorporated patients with prior 
history of PCa Gleason 3+3, this test has the potential 
to be used for monitoring patients on active 
surveillance. However, additional study with large 
number of patients is needed to explore the value of 
this test in active surveillance. Patients who are 
negative for specific cut-off point at the initiation of 
the active surveillance can be monitored using this 
test.  
While the testing predicts biopsy results, it does 
not provide information on the prostatectomy results. 
Long follow up and correlation with prostatectomy 
results is needed in future studies for selecting more 
precise cut-off points. We expect underestimation of 
the aggressiveness or the grade of the cancer as well 
as missing cancers on biopsy16. Therefore, correlation 
with prostatectomy or fusion biopsy is necessary for 
better evaluation of the reliability of such testing. 
However, because of the expected underestimation of 
cancer, we expect that the specificity of our test might 
improve when correlated with fusion biopsy or 
prostatectomy data. Furthermore, recent study 
suggested that not all Gleason 3+4 will have 
aggressive disease17. Some patients with Gleason 3+4 
detected in <10% of the tumor may have indolent 
disease. This is another limitation of this study that 
should be addressed in future studies.  
Conclusions 
In summary, the results of this multi-center, 
community-based trial for the validation of a 
urine/plasma test for the prediction of prostate 
biopsy results in the purpose of reducing unnecessary 
biopsy prove that the selected biomarkers are reliable 
and provide reproducible results, but the addition of 
clinical information in the test algorithm improves the 
sensitivity and NPV of the test significantly. The test 
is practical and less dependent on PSA or its isoforms 
and can be used for early detection of prostate cancer 
as well as for monitoring patients on active 
surveillance as well as watchful waiting. 
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